Tandem Diabetes announces NEJM publication of study on t:slim X2 insulin pump

The company states: "Tandem Diabetes announced publication of results from the Pediatric Artificial Pancreas Clinical Trial by the New England Journal of Medicine showing an approximate 3-hour per day increase in time in range in children ages 2-5 years old using the t:slim X2 insulin pump with Control-IQ advanced hybrid closed-loop technology compared to those on a standard insulin pump or multiple daily injections. All participants were using a Dexcom G6 Continuous Glucose Monitoring System. Results observed in this randomized, controlled trial for subjects using Control-IQ technology, an automated insulin delivery system, were immediate, sustained, and observed across the spectrum of patient characteristics including race-ethnicity, parental education, family income, baseline glycated hemoglobin level, virtual vs. in-person training format, and pre-study insulin delivery method. Subjects with higher baseline hemoglobin A1c values experienced greater improvements in time in range and A1c during the study."